MASHINIi

Marker Therapeutics, Inc..

MRKR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. Their MultiTAA-specific T cell technology platform is designed to stimul...Show More

Ethical Profile

Mixed.

Marker Therapeutics focuses on developing therapies for serious illnesses, with clinical data for MT-601 showing a 78% objective response rate and 44.4% complete response rate in lymphoma patients. The company also received a $2 million NIH grant for AML therapy development. However, critics point to Marker Therapeutics' engagement in animal testing for research, leading to its inclusion on the Cruelty Free Investing list. Furthermore, the company experienced a data breach in 2021, where reports suggest names, dates of birth, Social Security numbers, and protected health information were compromised.

Value Scores

Better Health for All40
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-70
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-20
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

40

Marker Therapeutics is a clinical-stage immuno-oncology company focused entirely on developing T cell-based immunotherapies for cancer, indicating its entire business is devoted to health improvement. Its lead product candidate, MT-601 for lymphoma, demonstrated a 78% objective response rate and a 44.4% complete response rate in the Phase 1 APOLLO study.

1
The company's MultiTAA-specific T cell therapies have been well-tolerated in over 200 patients across clinical trials.
2
Specifically for MT-601, no dose-limiting toxicities or immune-effector cell associated neurotoxicity syndrome (ICANS) were reported, with only one case of Grade 1 cytokine release syndrome (CRS) observed in the APOLLO study.
3
In 2024, the company's R&D expenses were $13.5 million, with $13 million in non-dilutive funding from CPRIT and NIH SBIR specifically supporting clinical programs, demonstrating a complete allocation of R&D to health improvement.
4
Marker Therapeutics also has an Expanded Access Policy that outlines ethical considerations, patient safety, and compliance with FDA guidelines for investigational therapies, prioritizing clinical trials while offering access under strict criteria.
5

Fair Money & Economic Opportunity

0

No evidence available to assess Marker Therapeutics, Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No evidence available to assess Marker Therapeutics, Inc. on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

No specific, concrete data points were found in the provided articles to assess Marker Therapeutics, Inc. against any of the Fair Trade & Ethical Sourcing KPIs, including fair trade certifications, audit frequency, forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend.

1
discusses product traceability for patient safety, but this does not provide evidence for supplier provenance data as defined by the 'traceability_coverage' KPI.
2

Honest & Fair Business

0

No evidence available to assess Marker Therapeutics, Inc. on Honest & Fair Business.

Kind to Animals

-70

Marker Therapeutics, Inc. engages in animal testing for medical analysis and clinical research, leading to its inclusion on a 'Cruelty Free Investing' list for exploiting animals.

1
There is no evidence that any of the company's products are certified cruelty-free, and no certifications related to animal welfare are mentioned in the provided articles.
2
The company's engagement in animal testing, without any mention of a formal policy to restrict or reduce it, or any ethical oversight, indicates a lack of a strong animal testing policy.

No War, No Weapons

0

No evidence available to assess Marker Therapeutics, Inc. on No War, No Weapons.

Planet-Friendly Business

-20

Marker Therapeutics, Inc. reported no regulatory actions, violations, fines, or compliance issues in its 2024 year-end summary.

1
For all other environmental KPIs, the provided articles explicitly state that no data was found or provided, or that the reports focused on financial and clinical results rather than environmental metrics.

Respect for Cultures & Communities

0

No data was found in the provided articles to assess MRKR.US against the 'Respect for Cultures & Communities' ethical value. Both articles explicitly stated that no relevant data could be extracted or was found for the requested metrics.

1

Safe & Smart Tech

0

No specific, concrete data points were found in the provided articles to assess Marker Therapeutics, Inc. (MRKR.US) against the Safe & Smart Tech ethical value. Article

1
, which pertains to Marker Therapeutics, Inc., explicitly states it contains no quantitative data or specific details relevant to the listed metrics.
2
Articles
3
and
4
refer to different entities, 'The Marker Group, Inc.' and 'Marker.io', respectively, and therefore their information cannot be attributed to Marker Therapeutics, Inc. as per the assessment rules.

Zero Waste & Sustainable Products

0

No data was available from the provided articles to assess Marker Therapeutics, Inc. against the Zero Waste & Sustainable Products ethical value. Both articles indicated that the requested pages could not be found, preventing any extraction of relevant information regarding waste diversion, product recyclability, packaging sustainability, or any other related KPIs.

1

Own Marker Therapeutics, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.